TGFB1 and breast carcinoma: A corresponding study by Mariathasan et al. demonstrated that the combination of pan-anti-TGFβ and anti-PD-L1 therapies induced complete regression (70%) in a transplantable model of mouse mammary carcinoma compared to 0% and 10% with either therapy alone, respectively12.